Human herpesvirus 6 (HHV-6) persists after primary infection at low level in blood and may reactivate in immunosuppressed patients, especially recipients of haematopoietic stem cell transplant (HSCT) causing encephalitis, engraftment failure, hepatitis and fever. 1, 2 In contrast to this situation some individuals have persistent, very high levels of HHV-6 DNA in blood due to chromosomal integration. 3 Chromosomal integration of HHV-6 (CHHV-6) was first described by Luppi et al. 4 in patients without any of the clinical manifestations of HHV-6 disease. Later, Daibata et al. 5 showed the inheritance of integrated HHV-6 DNA through two generations. Indeed, it seems that HHV-6 may be found in every cell of the body since it has been found not only in blood but also in the hair follicles of individuals with CHHV-6, and in both cases there is at least one copy of HHV-6 DNA per cell. 3 CHHV-6 is a relatively common phenomenon being found in 0.2 to 2.9% of the human population. 6, 7 It is to be predicted therefore that occasionally an allogeneic HSCT recipient or donor will have CHHV-6. Clark et al. 8 have reported such a situation with a graft from a donor with CHHV-6 to a patient originally without viral integration; there was consequent transmission of CHHV-6 via haematopoietic stem cells to the donor and an enormous increase in the amount of HHV-6 DNA in blood. Here, we report the opposite donor-recipient combination: a recipient with CHHV-6 who received a graft from a donor without integrated HHV-6.
In July 2003, in his second complete remission 2.5 years after the primary diagnosis, a 7-year-old boy underwent allogeneic HSCT for a relapse of ALL. After conditioning therapy (fractionated total body irradiation-12 Gy, etoposide and antithymocyte globulin), he received peripheral blood stem cells from an unrelated donor HLA matched in nine out of ten alleles. Aciclovir prophylaxis against herpes simplex virus infection was started during the conditioning. A full tri-lineage engraftment was confirmed with granulocytes engrafted on day þ 5 (ANC 40.5 Â 10 9 /l) and platelets on day þ 17 (untransfused platelet count 420 Â 10 9 /l). Acute GvHD grade II manifested on day þ 19 and was successfully treated with corticosteroids. One month after HSCT, BK virus-positive haemorrhagic cystitis occurred for which he received hyperhydration. No further severe complications were detected in the later post transplant period. The patient is currently at three years after HSCT without any clinical problems, has stable complete donor chimaerism in his blood and is in continuous remission of his leukaemia.
Viral loads in peripheral blood were regularly monitored for CMV, EBV and HHV-6 9 as part of standard post transplant surveillance. The viral loads were quantified using real-time PCR for viral DNA and normalized to 100 000 human genome equivalents in comparison with the quantity of albumin gene DNA in the sample.
10 CMV and EBV DNA loads were repeatedly negative or very low. However, the situation with HHV-6 was strikingly different; during conditioning therapy the first test for the presence of HHV-6 DNA detected an extremely high load of 490 000 normalized copies in peripheral blood, although there was no sign of HHV-6 related clinical complications. The subtype of the virus was determined as HHV-6 A by nested PCR and sequencing. In view of the apparent absence of HHV-6 disease, it was decided to continue with the HSCT but without antiviral therapy against the virus and with frequent monitoring of HHV-6 during the post transplant period. The level of HHV-6 DNA decreased rapidly after the transplant coincided with engraftment of the donor blood cells (Figure 1 ), and no clinical or laboratory signs of HHV-6-related complications were present during the post transplant period. The median of normalized viral DNA load in blood post transplant was 16, that is a 1000-fold lower compared to that pretransplant, and remained at this level throughout three years of surveillance.
Following the report by Ward et al. 3, we tested for the presence of HHV-6 DNA in the sample of allogeneic graft and found none. We also tested several archived pretransplant blood samples and the patient's hair follicles taken three years after HSCT. The HHV-6 DNA load in blood had been persistently very high including the first sample available for testing more than three years before transplantation and was also present at high level in hair follicles (Figure 1) . Notably the level of HHV-6 DNA per genome equivalent was about 1.
Thus, we demonstrate a decrease of HHV-6 DNA in our patient's blood within two weeks of transplantation, which is the converse of the increase described by Clark et al., 8 in the case of an integration-negative patient receiving an HSCT from a donor with CHHV-6. In our case, the high levels of HHV-6 DNA in the recipient's blood before transplantation, and also in hair follicles confirm the presence of CHHV-6 and the precipitous decrease in HHV-6 DNA level after transplantation is due to the replacement of the recipient's haemopoietic system with that of the CHHV-6 negative donor. However, since HHV-6 DNA was found in the recipient's hair follicles after transplantation, it is clear that other non-haematopoietic cells in the recipient's body still had CHHV-6, thus accounting for the persistent but low level of DNA in blood after transplantation, which is most likely due to the release of chromosomal DNA from non-haemopoietic cells during inflammation, GvHD and so on. Unfortunately, pre-transplant samples were not available to test retrospectively by FISH for HHV-6 DNA chromosomal sequences using the method described by Clark et al. 8 However, we recently encountered another similar case of a recipient with CHHV-6, and in this instance were able to confirm CHHV-6 by FISH (data not shown). Finally, our case also confirms that an extremely high HHV-6 viral load by itself without relevant symptoms of disease should not be an indication for antiviral drug treatment until the possibility of CHHV-6 has been ruled out. White blood cell count *10e9/ ml
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